HER2-Positive Breast Cancer

>

Latest News

Targeted Therapy Options for HER2+ Breast Cancer
Targeted Therapy Options for HER2+ Breast Cancer

January 13th 2024

A Satellite Session, involving members from US Oncology, focused on treatment options for patients with HER2-positive metastatic breast cancer.

T-DXd Yields Responses in HER2+ Breast Cancer with Brain Metastases
T-DXd Yields Responses in HER2+ Breast Cancer with Brain Metastases

October 21st 2023

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.
Tucatinib/T-DM1 Yields ‘Encouraging’ PFS in Unresectable HER2+ Breast Cancer

August 31st 2023

Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.
Trastuzumab Deruxtecan Receives Chinese Approval in HER2-Low Breast Cancer

July 15th 2023

Hospitalization rates appear to be comparable between patients receiving trastuzumab deruxtecan and trastuzumab emtansine for HER2-positive breast cancer in the phase 3 DESTINY-Breast03 study.
T-DXd May Maintain HRQOL, Delay Deterioration in HER2+ Metastatic Breast Cancer

May 22nd 2023

Video Series
Video Interviews
Podcasts

More News